For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...

A review of studies on communication between the nervous and immune systems redefines the neuroimmune connectome with a focus on health and disease, and discusses how the latest techniques can ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ESSA Pharma between ...

Will Nightingale, Reviews Editor The driving position in the Nissan Qashqai is superb. The driver's seat is comfy, and lines up well with the pedals and steering wheel (which is height and reach ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 (Ra-223) for androgen receptor pathway inhibitor (ARPI)–naive metastatic ...

Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") and certain officers.  The class action, filed in the United States District Court ...